Chong Hua Hospital Mandaue Offers New Hope for Patients with Neuroendocrine Tumors

Chong Hua Hospital Mandaue, through its Nuclear Medicine and Molecular Imaging Services, has achieved another milestone in Theranostics with the administration of Lutetium-177 DOTATATE therapy for Neuroendocrine Tumors, a type of targeted Peptide Receptor Radionuclide Therapy.

This therapy offers a treatment option that is designed specifically to target tumor or cancer cells directly by attaching to the specific receptors found in the Neuroendocrine Tumors. This helps to deliver radiation to the tumor cells while limiting exposure to nearby healthy tissues resulting to minimal side effects.

This milestone highlights the capability of Nuclear Medicine and Molecular Imaging Services in Chong Hua Hospital Mandaue to provide advanced Theranostic services, including Lu-177 DOTATATE therapy for patients with Neuroendocrine Tumors.

For inquiries on Lutetium-177 Dotatate Therapy, call: 

Nuclear Medicine and Molecular Imaging Services
(032) 233 8000 local 8120/8122 or 0968 877 2230